Compare Alnylam Pharmaceuticals, Inc. (ALNY) vs Thomson Reuters Corp (TRI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Alnylam Pharmaceuticals, Inc. vs Thomson Reuters Corp — how do they compare? Alnylam Pharmaceuticals, Inc. trades at $223.17 (market cap $29.60B), while Thomson Reuters Corp trades at $102.46 (market cap $45.38B). The key difference: Thomson Reuters Corp is the larger of the two by market cap, and Thomson Reuters Corp pays a 2.5% dividend while Alnylam Pharmaceuticals, Inc. pays none. Which is the better fit depends on your goals.
| ALNY | TRI | |
|---|---|---|
Market Cap | $29.60B | $45.38B |
Sector | Health | Industrials |
52-Week High | $491.22 | $178.77 |
52-Week Low | $205.48 | $76.55 |
Enterprise Value | $27.56B | $48.00B |
Dividend Yield | — | 2.5% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALNY trades at $222.54, up 2.56% today, amid a bearish technical signal with support at $218 and resistance at $223. The company reported strong revenue growth to $3.71B in 2025 and turned profitable with net income of $313.75M, though recent Q2 2026 earnings missed estimates. Analyst consensus remains bullish with a $370.07 price target, but multiple law firms are investigating potential securities fraud, creating near-term uncertainty.
The outlook is mixed: robust fundamentals and analyst support suggest long-term upside, but legal risks and recent earnings volatility pose significant headwinds. Investors face tension between strong profitability metrics and heightened sentiment risks from ongoing investigations.
Thomson Reuters (TRI) trades at $104.36, up 2.48% today, with a bullish technical signal and strong support at $102. The company reported Q2 2026 earnings of $0.99 per share, beating estimates, and raised full-year revenue guidance. Fundamentals show robust profitability with a 21.22% net income margin and 8% organic revenue growth, though cash flow trends indicate recent net outflows.
Outlook remains positive driven by AI product adoption and recurring revenue growth, but risks include execution on tech transitions and competitive pressures. Analysts project a 29.8% upside to the $124 high target, with a majority recommending Buy.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.
Read more on ALNY →About Thomson Reuters Corp
Thomson Reuters is the result of the $17.6 billion megamerger of Canada's Thomson and the United Kingdom's Reuters Group in 2008 and the 2018 carve-out of its finance and risk business, Refinitiv, in which it holds a 45% stake. In 2019, the company agreed to exchange its 45% stake in Refinitiv for a 15% stake in LSE, which closed in early 2021. Since the divestiture, the company is more concentrated on selling its flagship legal data and software, Westlaw, and its tax accounting software, Onesource. Reuters sees roughly 80% of revenue and 70% of expenses attributed to the United States, while the remainder (largely through the global print and Reuters News segments) is distributed across Latin America, Europe, the Middle East, Africa, and Asia-Pacific.
Read more on TRI →
